- Went public, Oct 2015
- Raised $100M funding round, May 2024
- Raised $150M funding round, Feb 2018
About
Novocure is a commercial-stage oncology company developing a novel, proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers.
TTFields are low-intensity, intermediate-frequency alternating electric fields that disrupt mitosis and cytokinesis. TTFields exert sufficient physical force on charged cellular components to stop normal cell-division processes, specifically the formation of the mitotic spindle from tubulin dimer proteins. TTFields also exert a physical force on other components of the cell during division, causing cell death prior to division.
TTFields therapy is delivered using noninvasive, insulated transducer arrays that are placed directly on the skin in the region surrounding the tumor. The complete delivery system includes a portable electric field generator, transducer arrays, rechargeable batteries, and more. The portable therapy is designed to be worn continuously throughout the day and night.
Novocure received an FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small cell lung cancer.
Funding history · 3 rounds · $742.0M total
Q&A
- What is NovoCure's primary therapy?
- NovoCure develops Tumor Treating Fields (TTFields), a proprietary therapy that uses low-intensity, intermediate-frequency alternating electric fields to disrupt cancer cell division for the treatment of solid tumor cancers.
- When did NovoCure go public and on which exchange?
- NovoCure went public on NASDAQ in October 2015, raising $165 million with a valuation of $1.8 billion.
- What was NovoCure's most recent funding round?
- In May 2024, NovoCure secured $100 million in a funding round.
- What was a significant regulatory approval for NovoCure's therapy in October 2024?
- In October 2024, NovoCure's Optune Lua received FDA approval for the treatment of non-small cell lung cancer.
- What leadership change was announced in September 2024?
- In September 2024, NovoCure announced that CEO Asaf Danziger would retire, with CFO Ashley Cordova named as his successor.
- What was a key clinical trial update for NovoCure in June 2024?
- In June 2024, the METIS Phase 3 clinical trial met its primary endpoint, demonstrating a significant delay in time to intracranial progression with improved quality of life deterioration-free survival.
- What was a notable announcement regarding TTFields therapy for pancreatic cancer in December 2024?
- In December 2024, NovoCure's TTFields therapy met its study goals in a pancreatic cancer study, leading to an increase in NVCR stock.
- What strategic decision did NovoCure announce in November 2023?
- In November 2023, NovoCure announced a portfolio prioritization and strategic restructuring plan focused on near-term growth drivers and an accelerated path to profitability.
- What was a significant employee-related event for NovoCure in December 2023?
- In December 2023, NovoCure announced plans to lay off 200 employees.
- What was a recent appointment to NovoCure's leadership team in January 2024?
- In January 2024, NovoCure appointed Dr. Nicolas Leupin as Chief Medical Officer.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | novocure.com |
|---|---|
| linkedin.com/company/105770 | |
| YouTube | youtube.com/channel/UCuzA71KFInZJKm9B24mBJZQ |
Identifiers & details
| Founded | 1999-4 |
|---|---|
| Employees (exact) | 1449 |
| Offices | Mnchen; Saint Helier; New York; Malvern; Japan; Root; Portsmouth |
| Market cap | $1.4B |
| Status reason | Public on NASDAQ on Oct, 2015 |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2020-11 | $575.0M | |||
| 2015-10 | $165.0M |